enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Lifileucel - Wikipedia

    en.wikipedia.org/wiki/Lifileucel

    Lifileucel is the first tumor-derived T cell immunotherapy approved by the US Food and Drug Administration (FDA). [3] It was approved for medical use in the United States in February 2024. [ 2 ] [ 4 ]

  3. Tisagenlecleucel - Wikipedia

    en.wikipedia.org/wiki/Tisagenlecleucel

    Tisagenlecleucel is indicated for the treatment of those under 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse; or adults with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma ...

  4. Immune checkpoint - Wikipedia

    en.wikipedia.org/wiki/Immune_checkpoint

    CTLA-4: short for Cytotoxic T-Lymphocyte-Associated protein 4 and also called CD152, is the target of Bristol-Myers Squibb's melanoma drug Yervoy, which gained FDA approval in March 2011. Expression of CTLA-4 on Treg cells serves to control T cell proliferation. [37] [38]

  5. A cancer treatment that one expert called the 'most exciting ...

    www.aol.com/article/news/2017/08/30/a-cancer...

    The FDA approved Novartis's Kymriah, also known as tisagenlecleucel, a treatment for pediatric acute lymphoblastic lymphoblastic leukemia.

  6. Immunotherapy - Wikipedia

    en.wikipedia.org/wiki/Immunotherapy

    The first FDA-approved cell-based immunotherapy, [28] the cancer vaccine Sipuleucel-T is one example of this approach. [29] The Immune Response Corporation [30] (IRC) developed this immunotherapy and licensed the technology to Dendreon, which obtained FDA clearance.

  7. 2 Innovative Stocks That Could Deliver Outsize Returns - AOL

    www.aol.com/2-innovative-stocks-could-deliver...

    The company develops therapies based on tumor-infiltrating lymphocytes (TILs). ... Iovance earned approval from the U.S. Food and Drug Administration for Amtagvi, the first therapy for advanced ...

  8. US FDA approves Mesoblast's cell therapy for graft-versus ...

    www.aol.com/news/us-fda-approves-mesoblasts-cell...

    (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that occurs after a stem cell or bone marrow transplant called ...

  9. Checkpoint inhibitor - Wikipedia

    en.wikipedia.org/wiki/Checkpoint_inhibitor

    The first checkpoint antibody approved by the FDA was ipilimumab, approved in 2011 for treatment of melanoma. [2] It blocks the immune checkpoint molecule CTLA-4. Clinical trials have also shown some benefits of anti-CTLA-4 therapy on lung cancer or pancreatic cancer, specifically in combination with other drugs. [12] [13]